Skip to main content

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.00
+9.78 (4.00%)
AAPL  269.05
-1.32 (-0.49%)
AMD  259.65
+3.53 (1.38%)
BAC  53.56
+0.11 (0.21%)
GOOG  284.12
+2.30 (0.82%)
META  637.71
-10.64 (-1.64%)
MSFT  517.03
-0.78 (-0.15%)
NVDA  206.88
+4.39 (2.17%)
ORCL  257.85
-4.76 (-1.81%)
TSLA  468.37
+11.81 (2.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.